Evidence mapPaperPMID 17047217Full record

ArticleJAMA2006

Incidence, causes, and outcomes of dilated cardiomyopathy in children.

Jeffrey A Towbin, April M Lowe, Steven D Colan, Lynn A Sleeper, E John Orav, Sarah Clunie, Jane Messere, Gerald F Cox, Paul R Lurie, Daphne Hsu and 3 more

4 registry-linked trialsAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in JAMA, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 405 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
405citing papers in PubMed, 5 pooled it
19.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06012266 phase2unknown statusstarted 2024, after this paper: background citation

Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of Age

Ran2024Enrolled12Registered outcomes19Posted comparisons0ConditionsHeart FailureArmsDapagliflozin Tablet, Empagliflozin Tablets
Open the trial in the graph
NCT04222101 naterminatednot on this mapstarted 2019, after this paper: background citation

Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy

TypeinterventionalSponsorLe Bonheur Children's HospitalRan2019 to 2021Enrolled9ConditionsCardiomyopathy, Dilated, Cardiomyopathy, Hypertrophic, Insulin ResistanceArmsOral glucose tolerance test
NCT04844151 recruitingnot on this mapstarted 2022, after this paper: background citation

Acute Myocarditis Registry With Prognostic, Histologic, Immunologic, Biological, Imaging and Clinical Assessment

Typeobservational_patient_registrySponsorAssistance Publique - Hôpitaux de ParisRan2022 to 2041Enrolled1,400ConditionsMyocarditis
NCT06643442 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Repurposing Empagliflozin for Duchenne Muscular Dystrophy - Associated Cardiomyopathy: a Pharmacokinetics, Safety and Proof-of-concept Study Among Children 6-18 Years of Age

TypeinterventionalSponsorSebastiano LavaRan2025 to 2027Enrolled12ConditionsDMD-associated Dilated CardiomyopathyArmsEmpagliflozin Tablets
3 · Its place in the literature

Who cites it

405 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,030 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Brazilian Society of Cardiology Guideline on Myocarditis - 2022.Arquivos brasileiros de cardiologia · 2022
    Guideline
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

345 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Jeffrey A TowbinTexas Children's Hospital, Baylor College of Medicine, Houston, USA.
April M Lowe
Steven D Colan
Lynn A Sleeper
E John Orav
Sarah Clunie
Jane Messere
Gerald F Cox
Paul R Lurie
Daphne Hsu
Charles Canter
James D Wilkinson
Steven E Lipshultz
Harvard University Press · USBaylor College of Medicine · USNew England Research Institutes · USUniversity of Miami · USAlbany Medical Center Hospital · USColumbia University · USWashington University in St. Louis · US

Funding

TRANSLATIONAL THERAPEUTIC STRATEGIES IN ACUTE LYMPHOCYTIC LEUKEMIAP01CA068484 · DANA-FARBER CANCER INSTITUTE · 1995 to 2004
$15.6M
Zic3 functions in cardiovascular developmentP01HL067155 · BAYLOR COLLEGE OF MEDICINE · 2001 to 2005
$8.5M
Cardiovascular Status of HAART-Exposed Infants/ChildrenR01HL072705 · UNIVERSITY OF ROCHESTER · 2002 to 2005
$5.0M
PEDIATRIC CARDIOMYOPATHY REGISTRYR01HL053392 · UNIVERSITY OF ROCHESTER · 1995 to 2005
$4.6M
CARDIAC RISK FACTORS IN PEDIATRIC CANCER SURVIVORSR01CA079060 · UNIVERSITY OF ROCHESTER · 1998 to 2002
$1.1M
HAART Associated Cardiotoxicity in HIV-Infected ChildrenR01HL078522 · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2004 to 2005
$817k
PEDIATRIC LUNG &HEART COMPLICATIONS OF HIV INFECTIONN01HR096041 · CHILDREN'S HOSPITAL BOSTON · 1989 to 1999
NCI NIH HHS P01 CA68484NCI NIH HHS R01 CA79060NHLBI NIH HHS N01 HR96041NHLBI NIH HHS P01 HL67155NHLBI NIH HHS R01 HL53392NHLBI NIH HHS R01 HL72705NHLBI NIH HHS R01 HL78522
6 · The paper itself

Abstract

contextDilated cardiomyopathy (DCM) is the most common form of cardiomyopathy and cause of cardiac transplantation in children. However, the epidemiology and clinical course of DCM in children are not well established.

objectiveTo provide a detailed description of the incidence, causes, outcomes, and related risk factors for DCM in children. DESIGN AND

settingLongitudinal study based on a population-based, prospective cohort of children diagnosed as having DCM since January 1, 1996, at 89 pediatric cardiac centers and a retrospectively collected cohort of patients seen primarily at large tertiary care centers in North America and who had diagnoses between January 1, 1990, and December 31, 1995, and were enrolled through February 2003.

participantsA total of 1426 children from the United States and Canada diagnosed as having DCM at younger than 18 years. Primary DCM was determined by strict echocardiographic and/or pathologic criteria. Patients with disease due to endocrine, immunologic, drug toxicity, and other causes were excluded.

main outcome measuresAnnual incidence per 100,000 children; mortality; cardiac transplantation.

resultsThe annual incidence of DCM in children younger than 18 years was 0.57 cases per 100,000 per year overall. The annual incidence was higher in boys than in girls (0.66 vs 0.47 cases per 100,000; P<.001), in blacks than in whites (0.98 vs 0.46 cases per 100,000; P<.001), and in infants (<1 year) than in children (4.40 vs 0.34 cases per 100,000; P<.001). The majority of children (66%) had idiopathic disease. The most common known causes were myocarditis (46%) and neuromuscular disease (26%). The 1- and 5-year rates of death or transplantation were 31% and 46%, respectively. Independent risk factors at DCM diagnosis for subsequent death or transplantation were older age, congestive heart failure, lower left ventricular fractional shortening Z score, and cause of DCM (P<.001 for all).

conclusionsIn children, DCM is a diverse disorder with outcomes that depend largely on cause, age, and heart failure status at presentation. Race, sex, and age affect the incidence of disease. Most children do not have a known cause of DCM, which limits the potential for disease-specific therapies.

Indexed as

Cardiomyopathy, DilatedAdolescentCanadaChildChild, PreschoolDisease ProgressionFemaleHeart TransplantationHumansIncidenceInfantLongitudinal StudiesMaleRegistriesRisk FactorsSurvival Analysis

Identifiers

PMID17047217
OpenAlexW1974383169

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.